Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice. (February 2015)

• Record Type: Journal Article
• Authors: Armesto, Susana; Coto-Segura, Pablo; Mayorga, Jesús; Illaro, Aitziber; Santos-Juanes, Jorge
• Is Part Of: Journal of dermatological treatment. Volume 26:Number 1(2015:Feb.)
• Page Start: 49
• Page End: 53
• Publication Date: 2015-02
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2014.880775
• Languages: English
• ISSNs: 0954-6634

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objective</italic>: To assess the efficacy and safety of adalimumab in biologic naïve versus non-biologic naïve psoriasis patients.</p> <p> <italic>Methods</italic>: A retrospective multicenter study of patients with moderate-to-severe psoriasis treated uninterruptedly with adalimumab between 6 and 36 months.</p> <p> <italic>Results</italic>: A total of 100 patients (52 men, 48 women; mean age 45.5 years; 90% plaque-type psoriasis) were included. Previous treatments included biologics in 53 and non-biologic modalities in 47. The mean (SD) start Psoriasis Area and Severity Index (PASI) score was 15.9 (11.1) (range 2–55). The median follow-up was 18 months (interquartile range 10–24 months). Sixteen weeks after the start of treatment, 94% of the patients presented PASI 75 response, 76% PASI 90, and 39% were in complete remission (PASI 100). Similar findings were obtained in the groups of biologic naïve and non-biologic naive patients. At the final visit, around 37% in all groups were in complete remission. At the end of the study, 74 patients continued treatment with adalimumab (43 [91.5%] in the biologic naïve group and 31 [58.5%] in the non-biologic naïve group, <italic>p</italic> &lt; 0.001).</p> <p> <italic>Conclusion</italic>: This study confirms the efficacy and safety of adalimumab for moderate-to-severe psoriasis without differences between biologic naïve and non-naïve patients.</p> </abstract>